CTS™ OpTmizer™ T-Zell-Expansion SFM, Flaschenformat

Zitierungen und Referenzen (7)

Gibco™

CTS™ OpTmizer™ T-Zell-Expansion SFM, Flaschenformat

GIBCO OpTmizer™ CTS™ T-Cell Expansion SFM wurde entwickelt für das Wachstum und die Expansion humaner T-Lymphozyten. GIBCO OpTmizer™ CTS™ T-CellWeitere Informationen

Katalognummer	Menge
A1048501	1 Flasche

Katalognummer A1048501

Preis (EUR)

222,00

Menge:

1 Flasche

Preis (EUR)

222,00

GIBCO OpTmizer™ CTS™ T-Cell Expansion SFM wurde entwickelt für das Wachstum und die Expansion humaner T-Lymphozyten. GIBCO OpTmizer™ CTS™ T-Cell Expansions-Medium ist ein serum- und xenofreies 1X-Vollmedium, bestehend aus OpTmizer™ T-Cell Expansion Basal Medium (1 Liter-Flasche) und OpTmizer™ T-Cell Expansion Supplement (26 ml), die gemischt werden vor der Verwendung.

• Behält ähnliche Phänotypen und Funktionen (z. B. Zytokin-Sekretionsprofil) von polyklonal aktivierten und kultivierten T-Zellen bei, wie sie für herkömmliches serumsupplementiertes Medium beobachtet wurden
• Konsistente Leistung bei der Unterstützung der T-Zellexpansion
• Unterstützt T-Zellkulturen mit hoher Dichte (z. B. >3x10⁶ CD3+ T-Zellen/ml) in statischer Kultur

Mit OpTmizer™ T-Zellexpansion SFM, Wir bieten sowohl Grundlagen- als auch klinischen Forschungsgemeinschaften ein neues Instrument, um ihren Erfolg beim Wachstum menschlicher T-Zellen zu steigern. Es wurde speziell für ein hervorragendes Zellwachstum und eine überlegene Viabilität, weniger Variabilität und konsistentere Ergebnisse sowie leichteren Übergang von Forschungs- zu klinischen Anwendungen entwickelt.

Vorteile im Arbeitsablauf:
• Minimierung des Bedarfs an Einkauf, Lagerung und Qualifizierung von Serum und somit Reduzierung von Variabilität und Kosten
• Schnellere T-Zellexpansion, wodurch die Zykluszeit reduziert und die Produktivität gesteigert wird.
• Vollständiges serumfreies, xeno-freies Medium, das einen nahtlosen Übergang von der Forschung zu klinischen Anwendungen ermöglicht und die Arbeitsbelastung durch behördliche Vorschriften minimiert

Specifications

ZelltypT-Zellen

KulturmilieuCO₂

Endotoxin-GehaltSehr gering

Antibiotika inklusiveKeine Antibiotika

Anorganische SalzeKalzium, Magnesium

ProduktlinieCTS, OpTimizer

ProdukttypZell-Expansion Serum-freies Medium (SFM)

Reinheits- oder QualitätsgradForschungsqualität

Menge1 Flasche

KlassifikationSerumfrei, Xeno-frei

Culture TypeSuspensions-Zellkultur

FormFlüssig

Serum LevelSerumfrei

SterilitätSteril

Mit AdditivenHEPES, Phenolrot, Natriumpyruvat, Natriumhydrogencarbonat

Ohne AdditiveKein Glutamin

Unit SizeEach

Inhalt und Lagerung

OpTimizer™ T-Zellen-Basal-Expansionsmedium (1 x 1000 ml-Flasche): Bei 2 bis 8 °C lagern. Vor Licht schützen.

OpTimizer™ T-Zellen-Expansionszusatz (1 x 26 ml): Bei 2 – 8 °C im Dunkeln lagern.

Häufig gestellte Fragen (FAQ)

What is CTS?

The Gibco Cell Therapy Systems (CTS) portfolio of cell and gene therapy products are GMP manufactured, safety tested, and backed by regulatory documentation to support your transition from discovery through clinical and commercial manufacturing. Through our CTS solutions, we are committed to helping customers streamline therapeutic development, minimize risk, and ease the burden on their quality systems. Learn more here.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Do I need to order additional components with the CTS OpTmizer T Cell Expansion SFM (Cat. Nos. A1048501, A1048502, A1048503)?

The CTS OpTmizer T Cell Expansion SFM (Cat. Nos. A1048501, A1048502, A1048503) kit comes with OpTmizer T Cell Expansion Basal Medium and OpTmizer T Cell Expansion Supplement, which are mixed together prior to use. Depending on your protocol you may need to purchase T cell growth factors such as IL-2 (Cat. No. PHC0023) and L-glutamine (Cat. No. 25030) to form a complete medium. To boost growth of human T cells, human AB serum can be added. If desired, antibiotics such as Gentamicin (Cat. No. 15750), can also be added.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Will CTS OpTmizer T Cell Expansion SFM (Cat. No. A1048501, A1048502, A1048503) work with all types of T cells?

CTS OpTmizer T Cell Expansion SFM (Cat. No. A1048501, A1048502, A1048503) has been demonstrated to be effective for the ex vivo expansion of human CD3 T cells, including polyclonal T cell populations, antigen-specific T cells, tumor-infiltrating lymphocytes (TIL), cord blood T cells, regulatory T cells, T cells from HIV-infected donors, gene-modified T cells (both lenti- and MLV-based vectors), including cells of both the CD4+ and CD8+ phenotype.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Can CTS OpTmizer T Cell Expansion SFM (Cat. Nos. A1048501, A1048502, A1048503) be used for animal T cell cultures other than human?

CTS OpTmizer T Cell Expansion SFM (Cat. No. A1048501, A1048502, A1048503) has only been tested on human T cells.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Is there a difference in formulation of the CTS OpTmizer T Cell Expansion SFM between the bottle and bag packaging formats?

The bottle and bag packaging formats of the medium have the same formulation.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

View all CTS™ OpTmizer™ T-Zell-Expansion SFM, Flaschenformat FAQs

Zitierungen und Referenzen (7)

Zitierungen und Referenzen

Abstract

Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.

Authors:Janetzki S, Price L, Britten CM, van der Burg SH, Caterini J, Currier JR, Ferrari G, Gouttefangeas C, Hayes P, Kaempgen E, Lennerz V, Nihlmark K, Souza V, Hoos A,

Journal:Cancer Immunol Immunother

PubMed ID:19894047

'The choice of serum for supplementation of media for T cell assays and in particular, Elispot has been a major challenge for assay performance, standardization, optimization, and reproducibility. The Assay Working Group of the Cancer Vaccine Consortium (CVC-CRI) has recently identified the choice of serum to be the leading cause ... More

Impact of culture medium on the expansion of T cells for immunotherapy.

Authors:Sato K, Kondo M, Sakuta K, Hosoi A, Noji S, Sugiura M, Yoshida Y, Kakimi K,

Journal:Cytotherapy

PubMed ID:19903105

'BACKGROUND AIMS: Encouraging evidence of clinical benefits from cancer immunotherapy is beginning to accumulate in several clinical trials. Cancer immunotherapy is based on two main methods, active vaccination and cell-transfer therapy. The ex vivo expansion of T cells is required to monitor vaccine-induced antigen-specific T cells or prepare large numbers ... More

Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement.

Authors:Smith C, Økern G, Rehan S, Beagley L, Lee SK, Aarvak T, Schjetne KW, Khanna R

Journal:

PubMed ID:25671129

The manufacture of clinical grade cellular products for adoptive immunotherapy requires ex vivo culture and expansion of human T cells. One of the key components in manufacturing of T cell therapies is human serum (HS) or fetal bovine serum (FBS), which can potentially expose immunotherapy recipient to adventitious infectious pathogens ... More

Bioengineering and serum free expansion of blood-derived ?d T cells.

Authors:Sutton KS, Dasgupta A, McCarty D, Doering CB, Spencer HT

Journal:Cytotherapy

PubMed ID:27260209

'Cellular immunotherapy relies on several highly variable patient-specific parameters, such as (i) cell number before and after expansion, (ii) targeting of cells to tumors, (iii) cell survival and function after infusion, and (iv) on- and off-target adverse events. Cellular approaches such as the specific expansion of ?d T cells as ... More

A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies.

Authors:Lu TL, Pugach O, Somerville R, Rosenberg SA, Kochendefer JN, Better M, Feldman SA

Journal:Hum Gene Ther Methods

PubMed ID:27897048

The treatment of B-cell malignancies by adoptive cell transfer (ACT) of anti-CD19 chimeric antigen receptor T cells (CD19 CAR-T) has proven to be a highly successful therapeutic modality in several clinical trials.(1-6) The anti-CD19 CAR-T cell production method used to support initial trials relied on numerous manual, open process steps, ... More

View all CTS™ OpTmizer™ T-Zell-Expansion SFM, Flaschenformat citations